Breast Cancer Clinical Trial

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This laboratory study is collecting skin biopsy specimens from patients receiving irinotecan or gemcitabine for advanced solid tumors and using them to study change in DNA due to this treatment.

View Full Description

Full Description

OBJECTIVES:

Primary

Determine the level of p-Chk1 and phospho-histone 2AX (p-H2AX), an indicator of DNA damage, and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors.

Secondary

Characterize the method for measurement (immunohistochemistry).
Measure inter- and intra-patient variability for the biomarker.
Partially characterize the dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent.

OUTLINE: This is a multicenter study.

Patients undergo collection of 2 skin biopsies with hair follicles at 4 and 8 hours or at 4 and 6 hours after the start of irinotecan hydrochloride or gemcitabine hydrochloride treatment on day 1 of course 1. Repeat biopsies will be taken at 4, 6, or 8 hours after the start of irinotecan hydrochloride or gemcitabine hydrochloride on day 1 of 2 successive courses.

Tissue is examined by immunohistochemistry and possibly other methods for changes in p-Chk1 and pH2AX.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Diagnosis of advanced solid tumor malignancy (preferably colorectal, pancreatic, or breast cancer)
Scheduled to receive a standard dose, weekly regimen of either irinotecan hydrochloride or gemcitabine hydrochloride

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

No DNA-damaging agent within the past 13 days

Study is for people with:

Breast Cancer

Estimated Enrollment:

60

Study ID:

NCT00369109

Recruitment Status:

Completed

Sponsor:

Barbara Ann Karmanos Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Barbara Ann Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Christie Hospital NHS Trust
Manchester England, M20 4, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

60

Study ID:

NCT00369109

Recruitment Status:

Completed

Sponsor:


Barbara Ann Karmanos Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.